

Sudarshan Paramsothy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6748870/publications.pdf>

Version: 2024-02-01

45
papers

2,840
citations

394286

19
h-index

289141

40
g-index

47
all docs

47
docs citations

47
times ranked

3746
citing authors

#	ARTICLE	IF	CITATIONS
1	Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. <i>Lancet</i> , The, 2017, 389, 1218-1228.	6.3	908
2	Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1180-1199.	0.6	323
3	Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2019, 156, 1440-1454.e2.	0.6	290
4	Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions. <i>Current Gastroenterology Reports</i> , 2013, 15, 337.	1.1	210
5	Donor Recruitment for Fecal Microbiota Transplantation. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1600-1606.	0.9	122
6	Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. <i>Cell Host and Microbe</i> , 2020, 27, 823-829.e3.	5.1	110
7	Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 141-151.	3.7	104
8	Therapeutic faecal microbiota transplantation. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 97-105.	1.0	101
9	The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018, 11, 1558-1570.	2.7	80
10	Review article: acute severe ulcerative colitis "evidence" based consensus statements. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 127-144.	1.9	63
11	Defined microbiota transplant restores Th17/ROR γ ^{3t} regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21536-21545.	3.3	58
12	Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2020, 69, 801-810.	6.1	52
13	Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 292-301.	1.9	39
14	Gastroenterologist perceptions of faecal microbiota transplantation. <i>World Journal of Gastroenterology</i> , 2015, 21, 10907.	1.4	33
15	Epidemiology of inflammatory bowel disease in South America: A systematic review. <i>World Journal of Gastroenterology</i> , 2019, 25, 6866-6875.	1.4	30
16	Safety of drugs used for the treatment of Crohn's disease. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 357-367.	1.0	29
17	Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 275-292.	1.0	24
18	Fluorescein contrast in confocal laser endomicroscopy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 366-368.	8.2	23

#	ARTICLE	IF	CITATIONS
19	The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease. <i>Current Opinion in Pharmacology</i> , 2020, 55, 8-16.	1.7	22
20	An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 246-255.	1.4	22
21	Fecal microbiota transplantation: a new standard treatment option for Clostridium difficile infection. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 447-449.	2.0	21
22	Review of pregnancy in Crohn's disease and ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110162.	1.4	19
23	Emergent colectomy rates decreased while elective ileal pouch rates were stable over time: a nationwide inpatient sample study. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1771-1779.	1.0	16
24	Long-Term Bacterial and Fungal Dynamics following Oral Lyophilized Fecal Microbiota Transplantation in Clostridioides difficile Infection. <i>MSystems</i> , 2021, 6, .	1.7	16
25	Spp24 is associated with endocytic signalling, lipid metabolism, and discrimination of tissue integrity for "leaky-gut" in inflammatory bowel disease. <i>Scientific Reports</i> , 2020, 10, 12932.	1.6	13
26	Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy. <i>Gut</i> , 2021, 70, 2210-2211.	6.1	12
27	Is Crohn's Disease Ready for Fecal Microbiota Transplantation?. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 582-583.	1.1	11
28	Assisted Reproductive Technology in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2021, Publish Ahead of Print, .	0.2	11
29	High prevalence of Crohn disease and ulcerative colitis among older people in Sydney. <i>Medical Journal of Australia</i> , 2021, 214, 365-370.	0.8	10
30	Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210807.	1.4	10
31	Gastroenterologists' preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 976-983.	0.8	9
32	Resumption of oral intake following percutaneous endoscopic gastrostomy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1098-1101.	1.4	8
33	Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease. <i>World Journal of Gastroenterology</i> , 2022, 28, 2597-2608.	1.4	8
34	Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study. <i>BMJ Open</i> , 2021, 11, e042493.	0.8	6
35	Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1524-1532.	0.8	6
36	The Role of Biosimilars in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2016, 12, 741-751.	0.2	6

#	ARTICLE	IF	CITATIONS
37	Promise of Fecal Microbiota Transplantation Therapy in Pouchitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1107-1110.	1.1	5
38	680 LYOPHILIZED ORALLY ADMINISTERED FECAL MICROBIOTA TRANSPLANTATION IN THE MANAGEMENT OF ULCERATIVE COLITIS (LOTUS STUDY) – RESULTS FROM THE INDUCTION PHASE OF A RANDOMIZED CONTROLLED TRIAL. <i>Gastroenterology</i> , 2021, 160, S-135.	0.6	2
39	Ten-Year Retained Video Capsule With Crohn’s-Associated Small-Bowel Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, A29-A30.	2.4	1
40	Reply. <i>Gastroenterology</i> , 2019, 157, 1165-1166.	0.6	1
41	Oral faecal microbiota transplantation in ulcerative colitis – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 286-287.	3.7	1
42	Anorectal Lesion in a Middle-Aged Woman. <i>Gastroenterology</i> , 2012, 142, e1-e2.	0.6	0
43	Faecal microbiota transplantation as an elixir of youth. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 488-489.	0.7	0
44	Travel risk management. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 32-33.	1.4	0
45	Combination Therapy of Immunomodulators With Non-Anti-Tumor Necrosis Factor Agents in Inflammatory Bowel Disease: Need More Evidence?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	0